nach oben

Erschienen in:

04.06.2018 | Melanom | Dermatoonkologie

Immuncheckpointhemmer und Co.

Aktuelle Immuntherapien des malignen Melanoms

verfasst von: Dr. med. Katharina Pietschke, Dr. med. Diana Lomberg, PD Dr. med. Thomas Kurt Eigentler

Erschienen in: Im Fokus Onkologie | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch zielgerichtete Behandlungsoptionen und Immuncheckpointinhibitoren wurde die Prognose von Patienten mit metastasiertemMelanom deutlich verbessert. Dennoch bedarf es weiterer Forschungsbestrebungen. Zurzeit stehen zum Beispiel verschiedene Kombinationen von Checkpointinhibitoren untereinander und mit anderen Substanzen im Fokus der Forscher.

Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27(1):3–9.CrossRefPubMed

Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer-the role of sunlight. Adv Exp Med Biol. 2008;624:89–103.CrossRefPubMed

Hölzel D, Engel J. Epidemiologie von malignen Erkrankungen zwischen 20 und 30 Jahren 2011. https://www.onkopedia.com/de/wissensdatenbank/ wissensdatenbank/wissensdatenbank/heranwachsende-und-junge- erwachsene-aya-adolescents-and-young-adults/HoelzelAYA.pdf.

Garbe C et al. Diagnosis and treatment of melanoma: European consensus- based interdisciplinary guideline. Eur J Cancer. 2010;46(2):270–83.CrossRefPubMed

Green AC et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30(13):1462–7.CrossRefPubMed

Davies H et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRefPubMed

Eigentler TK et al. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 3.0-April 2018; AWMF-Register-Nummer: 032/024OL; http://www.awmf.org/uploads/tx_szleitlinien/032- 024OL_l_S3_Melanom-Diagnostik-Therapie-Nachsorge_2018-05.pdf

Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603–15.CrossRefPubMed

Gooden MJ et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.CrossRefPubMedPubMedCentral

10.

Yazdi AS et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol. 2006;126(2):393–8.CrossRefPubMed

11.

Schwartzentruber DJ et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27.

12.

Rosenberg SA et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308.CrossRefPubMedPubMedCentral

13.

Thurner B et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190(11):1669–78.CrossRefPubMedPubMedCentral

14.

Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17(2):117–27.CrossRefPubMed

15.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.CrossRefPubMed

16.

Stronen E et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352(6291):1337–41.CrossRefPubMed

17.

Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26(32):5275–83.CrossRefPubMed

18.

Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.CrossRefPubMedPubMedCentral

19.

Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.CrossRefPubMed

20.

Topalian SL et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–12.CrossRefPubMedPubMedCentral

21.

Taube JM et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.CrossRefPubMedPubMedCentral

22.

Ribas A et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016;315(15):1600–9.CrossRefPubMed

23.

Ribas A et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.CrossRefPubMed

24.

Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62.CrossRefPubMed

25.

Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.CrossRefPubMed

26.

Weber JS et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol.2015;16(4):375–84.CrossRefPubMed

27.

Höller C, Nguyen V. Nivolumab beim fortgeschrittenen, nicht-resezierbaren oder metastasierten Melanom. J Med Drug Rev. 2016;6:11–22.

28.

Hodi FS et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68.CrossRefPubMedPubMedCentral

29.

Dummer R et al. Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma. J Clin Oncol. 2018;36(Suppl 5):189.CrossRef

30.

Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270–1.CrossRefPubMed

31.

Ribas A et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Ann Oncol. 2017;28(Suppl 5):Abstr 1216O.

32.

Fountzilas C et al. Review: Oncolytic Virotherapy, updates and future directions. Oncotarget. 2017;8(60):102617–39.CrossRefPubMedPubMedCentral

33.

Puzanov I et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016;34(22):2619–26.CrossRefPubMed

34.

Pirard D et al. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology. 2004;208(1):43–8.CrossRefPubMed

35.

Bristol Myers Squibb. Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint 2017. https://news.bms.com/press-release/corporatefinancial-news/phase-3-study-evaluating%C2%A0-safetyand-efficacy-adjuvant-opdivo.

36.

Weide B et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res. 2016;22(22):5487–96.CrossRefPubMedPubMedCentral

37.

Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48–56.CrossRefPubMedPubMedCentral

38.

Spranger S et al. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5.CrossRefPubMed

39.

Restifo NP et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2):100–8.CrossRefPubMedPubMedCentral

40.

D’Urso CM et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991;87(1):284–92.CrossRefPubMedPubMedCentral

41.

Sucker A et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res. 2014;20(24):6593–604.CrossRefPubMed

42.

Koyama S et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.CrossRefPubMedPubMedCentral

Titel: Immuncheckpointhemmer und Co.
Aktuelle Immuntherapien des malignen Melanoms
verfasst von: Dr. med. Katharina Pietschke
Dr. med. Diana Lomberg
PD Dr. med. Thomas Kurt Eigentler
Publikationsdatum: 04.06.2018
Verlag: Springer Medizin
Schlagwörter: Melanom
Melanom
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Erschienen in: Im Fokus Onkologie / Ausgabe 6/2018
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI: https://doi.org/10.1007/s15015-018-3604-z

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Oftmals von Dauer: Schluckbeschwerden nach Thyreoidektomie

Immunonkologie: neue Perspektiven auch für ältere NSCLC-Patienten

Nationale Dekade gegen Krebs

Brustkrebs: Häufig Spätrezidive nach antihormoneller Therapie

CML in der Blastenkrise: Auch in der TKI-Ära noch schlechte Prognose

ESMO-Glossar zur Präzisionsmedizin